In the current study, we demonstrated that two biomarkers, ICAM-1 and PECAM-1, were significantly higher in the serum of patients associated with cognitive dysfunction, depression, vestibulocerebellar ataxia, and in the group of patients following chemotherapy. This evidence concerns the gene PECAM1 and depressive disorder.